Tirzepatide: A New Anti-Obesity Medication in Little Elm, TX
Obesity is a serious health condition that can be associated with some of the leading causes of death, like cardiovascular disorders. The rates at which both obesity and overweight in the United States are rising are quite alarming. Recently, the FDA has approved Tirzepatide injection (Zepbound) for chronic weight management in adults with obesity with a body mass index of 30 kg/m2 or greater as well as overweight individuals with a body mass index of 27 kg/m2 or greater and having at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.
To combat obesity and improve the quality of life of people in the U.S., The Food and Drug Administration (FDA) is always on the lookout for safe and effective treatment solutions.
Zepbound works by activating receptors of hormones secreted from the intestine (glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) to reduce appetite.
The significant reduction of your appetite makes you eat less, thereby reducing your calorie intake, which leads to weight loss. This medication is best combined with a low-calorie diet and increased physical activity for best results.
Tirzepatide was approved under the trade name Mounjaro to be used along with low-calorie diets and exercise to help improve blood sugar in adults suffering from type 2 diabetes mellitus.
Being overweight or obese comes with devastating health effects, and losing as little as 5% to 10% of body weight using Tirzepatide in combination with low-calorie diets and exercise will help reduce your risk of cardiovascular disease significantly.
Tirzepatide Once Weekly for the Treatment of Obesity
Obesity is a chronic disease, and Tirzepatide offers a once-weekly treatment for this chronic condition. Tirzepatide is a subcutaneous glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) agonist that can be used for chronic weight management.
It interacts with body receptors to reduce appetite by activating two gut hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
Tirzepatide is administered as a once-weekly injectable subcutaneously. Zepbound for obesity is administered by injection under the skin once weekly.
The dosage must be increased over four to 20 weeks to achieve the target doses of 5 milligrams (mg), 10 mg, or 15 mg maximum once weekly.
FDA Approves Tirzepatide Injection for Adults With Type 2 Diabetes
In May 2022, the U.S. Food and Drug Administration approved Mounjaro injection to improve glycemic control in adults with type 2 diabetes, in addition to diet and exercise.
Tirzepatide, the active ingredient in Mounjaro, was effective at improving blood sugar and was more effective than the other pharmacological therapies for diabetes mellitus, with which it was compared in clinical studies.
It’s a first-in-class medication of a brand-new drug class called glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, also known as GLP-1 and GIP receptor agonists.
It mimics the actions of two hormones, GLP-1 and GIP, that work together to stimulate insulin secretion and delay stomach emptying after a meal, signaling to the brain that you’re full.
Tirzepatide Triumphs in Significant Weight Reduction for People With Type 2 Diabetes
Obesity raises the risk of numerous weight-related issues, of which type two diabetes, cardiovascular diseases, and chronic kidney disease are leading the list. FDA-approved Tirzepatide for chronic weight management in adults because it has proven to be effective in weight reduction for people, including those with type 2 diabetes.
In clinical trials, up to 21% weight reduction was seen in those using Tirzepatide. Although weight reduction is a key component of type 2 diabetes management, few drugs exist with a double effect on both body weight and glycemic control.
This GIP and GLP-1 receptor agonist medication combines the action of the two hormones to synergize glucose and lipid homeostasis that regulates food consumption and appetite. Thus, the United States Food and Drug Administration (FDA) approved Tirzepatide for chronic weight management for people with type 2 diabetes.
You should also know that certain studies show that obese people with type 2 diabetes often have less weight reduction in response to anti-obesity medication treatment than those without diabetes.
Both 10 and 15 mg doses offer clinically significant bodyweight reductions and improved HbA1c and other cardiometabolic risk factors.
It helps obese adults with type 2 diabetes achieve a body weight reduction that exceeds the levels of weight reduction of other approved anti-obesity medications.
Tirzepatide Shows Success in Maintaining Weight Loss in Obese Adults
Tirzepatide doesn’t only help obese adults with type 2 diabetes achieve a health-impacting weight reduction, but it is also effective for weight loss in obese individuals without diabetes.
Clinical trial results show that patients lost an average of 22.5% of their body weight on Tirzepatide compared to diet and placebo.
Certain research has also shown that patients lost an average of 22.5% of their body weight on Tirzepatide, which is much compared to similar weight loss drugs like Wegovy and Saxenda, which reduce body weight by around 15% and 5%.
Tirzepatide Promotes Weight Loss in Patients With Obesity, Type 2 Diabetes
Tirzepatide is a once-weekly injectable medication approved to treat type 2 diabetes and also holds major potential as a weight loss medication for people with obesity. Overweight or obese participants without type 2 diabetes who took Tirzepatide, sold as the diabetes drug Mounjaro, lost an average of nearly 21% of their body weight at the highest dose studied.
The weight loss results in this study are far more than the ones seen in other FDA-approved medications. Tirzepatide is the first drug in the family of medications designed to target two hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, at the same time.
These two hormones maintain healthy blood sugar levels and send signals from the gut to the brain when people are full. A clinical trial found Tirzepatide, in this instance, to be more effective at controlling blood sugar and facilitating weight loss in type 2 diabetes patients than semaglutide (Ozempic) and Insulin.
Tirzepatide reduces hemoglobin A1C levels, which reflect average blood sugar levels over about three months, by 0.5% more than semaglutide and by about 1% more than insulin.
Impressive Results From Tirzepatide for People With Type 2 Diabetes And Obesity
Below are impressive results that people with type 2 diabetes and obesity achieved with the use of Tirzepatide:
“I started Tirzepatide on 5/26/23 weighing 200.5 lbs. I worked out 3-5 days per week but was not losing weight. I am down 15 lbs and have lost all cravings. I listen to my body and eat when I am hungry. I have zero side effects.”
“I am an African American female 58 years old 5 ‘8’’ weighing an unbelievable 270lbs 12/30/22 I asked my doctor if I could take this medication and now here we are. 8 weeks later. I currently weigh 244.6 lbs, I lost 16 lbs in the first 3 weeks. I was extremely shocked and a little worried. My health is a constant concern, I suffer from chronic allergies and frequently took steroid shots to manage the problem but brought on weight gain. I am feeling better about myself. No headaches, no vomiting, slight constipation. I am attempting to make this a life change with better food selections and exercise regimen to keep me on track.”
Tirzepatide Trial Shows an Additional 21.1% Weight Loss.
Research has shown that Tirzepatide works for weight loss by decreasing food intake and modulating fat utilization. Certain researchers have also compared the efficacy and safety of a placebo for a total of 72 weeks after a 12-week intensive lifestyle intervention, and up to 21.1% weight loss was observed.
FAQ
How much weight can you lose on Tirzepatide?
People can lose significant weight: On average, one can lose around 20 percent of their body weight.
Can doctors prescribe Tirzepatide for weight loss?
Yes, doctors can prescribe Tirzepatide for weight loss. You can reach out to your physician to get a Tirzepatide prescription for weight loss. Your doctor will review your medical history and conduct some physical evaluations before prescribing the medication for you.
What BMI is required for Tirzepatide?
Obese adults with a BMI ≥ 30 kg/m2 or overweight with a BMI ≥ 27 kg/m2 and at least have one weight-related comorbid condition are good candidates for Tirzepatide.
Can you get Tirzepatide in pill form?
No, you can’t get Tirzepatide in pill form at the moment. However, some medical professionals are working on a pill form for Tirzepatide, which is already at the clinical trials stage.
What injection is best for weight loss?
Tirzepatide injection is one of the best medications for weight loss.
How do I start Tirzepatide?
You start Tirzepatide by injecting 2.5 milligrams (mg) under the skin once a week for four weeks. Your doctor may increase your dose as required.
Is it a pill or an injection?
Tirzepatide is currently only available in injection form. Processes are ongoing to make Tirzepatide available in pill forms.
